1
|
Peng J, Qiu J, Cheng D, Rao Y, Mao M, Qiu K, Li J, Chen F, Liu F, Liu J, Mu X, Yu W, Zhang W, Xu W, Zhao Y, Ren J. Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Paranasal Sinuses. Otolaryngol Head Neck Surg 2023; 168:1107-1118. [PMID: 36939485 DOI: 10.1002/ohn.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 09/26/2022] [Accepted: 10/18/2022] [Indexed: 02/11/2023]
Abstract
OBJECTIVE We aimed to compare clinical and survival differences between B-cell (B-NHL) and NKT-cell non-Hodgkin lymphomas (NKT-NHL) located in the nasal cavity (NC), nasopharynx, and paranasal sinuses, which are always categorized as one sinonasal type. STUDY DESIGN Patients diagnosed with primary B-NHL and NKT-NHL in the nasal cavity, nasopharynx, and paranasal sinuses from Surveillance, Epidemiology, and End Results (SEER) database were included (1975-2017). SETTING Population-based cohort study. METHODS We conducted univariate and multivariate Cox regressions and Kaplan-Meier analysis to examine survival outcomes of B/NKT-NHL in the nasal cavity, nasopharynx, and paranasal sinuses, respectively. RESULTS Overall, most B-NHL cases originated from the nasopharynx, while the majority of NKT-NHL cases occurred in the nasal cavity. Notably, the cancer-special survival (CSS) outcomes improved significantly in all sinonasal B-NHL cases over time, whereas no such improvement trend was observed in each sinonasal NKT-NHL type. Additionally, increasing age was linked with an elevated risk of death in B-NHL, particularly in the nasal cavity (Hazard ratio [HR]: 3.37), rather than in NKT-NHL. Compared with B-NHL, the adverse effect of a higher stage on CSS was more evident in NKT-NHL, particularly in its nasopharynx site (HR: 5.12). Furthermore, radiotherapy was beneficial for survival in patients with sinonasal B-NHL and NKT-NHL, except in the nasopharynx NKT-NHL. However, chemotherapy has only been beneficial for CSS in patients with paranasal sinuses B-NHL (HR: 0.42) since 2010, rather than in other types of B/NKT-NHL. CONCLUSION Although B-NHL and NKT-NHL in the nasal cavity, nasopharynx and paranasal sinuses have similar anatomical locations, their clinicodemographics and prognoses are largely different and should be treated and studied as distinct diseases.
Collapse
Affiliation(s)
- Jiajia Peng
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Jianqing Qiu
- Department of Oto-Rhino-Laryngology, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
| | - Danni Cheng
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Yufang Rao
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Minzi Mao
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Ke Qiu
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Junhong Li
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Fei Chen
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Feng Liu
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Jun Liu
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
| | - Xiaosong Mu
- Department of Oto-Rhino-Laryngology, Langzhong People's Hospital, Sichuan, Langzhong, China
| | - Wenxin Yu
- Department of Oto-Rhino-Laryngology, Suining People's Hospital, Sichuan, Suining, China
| | - Wei Zhang
- Department of Oto-Rhino-Laryngology, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
| | - Wei Xu
- Department of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, Ontario, Canada
| | - Yu Zhao
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.,Department of Oto-Rhino-Laryngology, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
| | - Jianjun Ren
- Department of Oto-Rhino-Laryngology, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.,Department of Oto-Rhino-Laryngology, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
2
|
Fuh FK, Looney C, Li D, Poon KA, Dere RC, Danilenko DM, McBride J, Reed C, Chung S, Zheng B, Mathews WR, Polson A, Prabhu S, Williams M. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol 2017; 174:628-640. [PMID: 28009435 PMCID: PMC5368047 DOI: 10.1111/bph.13697] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Revised: 11/11/2016] [Accepted: 12/15/2016] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND AND PURPOSE CD22 and CD79b are cell-surface receptors expressed on B-cell-derived malignancies such as non-Hodgkin's lymphoma (NHL). An anti-mitotic agent, monomethyl auristatin E, was conjugated to anti-CD22 and anti-CD79b antibodies to develop target-specific therapies for NHL. The mechanism of action (MOA) and pharmacological and pharmacokinetic (PK) profiles of these antibody-drug conjugates (ADCs) were investigated in cynomolgus monkeys. EXPERIMENTAL APPROACH Animals were administered anti-CD22 or anti-CD79b ADCs, respective unconjugated antibodies or vehicle. Pharmacodynamic effects on total and proliferating B cells and serum PK were then assessed. Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of the ADCs were evaluated in vitro. KEY RESULTS Depletion of B cells was observed after administration of either ADC or the respective unconjugated antibodies. An extended duration of depletion was observed in animals administered ADCs. Similarly, preferential depletion of proliferating B cells in blood and germinal centre B cells in spleen were only observed in animals administered ADCs. Serum PK profiles of ADCs and respective unconjugated antibodies were comparable. In vitro, anti-human CD22 and anti-human CD79b antibodies showed no or only moderate ADCC activity, respectively; neither antibody had CDC activity. CONCLUSIONS AND IMPLICATIONS The findings support the proposed MOA: initial depletion of total B cells by antibody-mediated opsonization, followed by preferential, sustained depletion of proliferating B cells by the auristatin conjugate due to its anti-mitotic action. Delivering potent anti-mitotic agents to B cells via the specificity of monoclonal antibodies provides a means to eliminate pathogenic B cells in NHL with improved risk-benefit profiles over traditional chemotherapeutics.
Collapse
Affiliation(s)
- Franklin K Fuh
- Department of Pharmacodynamic BiomarkersGenentech, Inc.South San FranciscoCAUSA
| | - Caroline Looney
- Department of Pharmacodynamic BiomarkersGenentech, Inc.South San FranciscoCAUSA
| | - Dongwei Li
- Department of Pharmacokinetic and Pharmacodynamic SciencesGenentech, Inc.South San FranciscoCAUSA
| | - Kirsten A Poon
- Department of Safety and ToxicologyGenentech, Inc.South San FranciscoCAUSA
- Denali Therapeutics, Inc.South San FranciscoCAUSA
| | - Randall C Dere
- Department of BioAnalytical Research and DevelopmentGenentech, Inc.South San FranciscoCAUSA
| | | | - Jacqueline McBride
- Department of Pharmacodynamic BiomarkersGenentech, Inc.South San FranciscoCAUSA
| | - Chae Reed
- Department of BioAnalytical Research and DevelopmentGenentech, Inc.South San FranciscoCAUSA
| | - Shan Chung
- Department of BioAnalytical Research and DevelopmentGenentech, Inc.South San FranciscoCAUSA
| | - Bing Zheng
- Department of Immunology ResearchGenentech, Inc.South San FranciscoCAUSA
| | | | - Andrew Polson
- Department of Immunology ResearchGenentech, Inc.South San FranciscoCAUSA
| | - Saileta Prabhu
- Department of Pharmacokinetic and Pharmacodynamic SciencesGenentech, Inc.South San FranciscoCAUSA
| | - Marna Williams
- Department of Pharmacodynamic BiomarkersGenentech, Inc.South San FranciscoCAUSA
- MedImmune, GaithersburgMDUSA
| |
Collapse
|